2nd Highly Potent APIs Summit
Days
Hours
Minutes
Seconds
e
g
i
s
t
e
r
N
o
w
About the event
Advancing Highly Potent API Manufacturing in Europe
The pharmaceutical industry is at the core of modern healthcare, and highly potent active pharmaceutical ingredients (HPAPIs) are driving breakthroughs in oncology, targeted therapies, and antibody-drug conjugates (ADCs). With demand for potent compounds skyrocketing, Europe is stepping up its game, pushing for stronger HPAPI development and manufacturing capabilities to boost supply security, operator safety, and therapeutic innovation.
Growing oncology pipelines and major CDMO and pharma investments are accelerating HPAPI capacity expansions, but scaling production brings key challenges - from containment and occupational exposure to ensuring safe, compliant, and efficient Highly Potent API Manufacturing and HPAPI Process Development.
As Europe continues investing heavily in potent compound capacity, the summit will also address the growing demand for advanced HPAPI Containment strategies and scalable Highly Potent API Manufacturing methodologies. This HPAPI event will explore how industry leaders are delivering safe, high-quality potent compounds through advanced containment, isolator technology, process intensification, and next-generation facility design. Attendees of this Highly Potent APIs Summit will gain insights into operator safety, regulatory compliance, and innovations shaping the future of HPAPI development in Europe.
Safe and Scalable HPAPI Solutions at the Highly Potent APIs Expo
The 2nd Highly Potent APIs Summit, a leading HPAPI Conference and Highly Potent API Manufacturing event, will explore how modern technologies and innovations are transforming potent compound development and production.
As the industry faces increasing pressure to scale efficiently while protecting operators and patients, topics such as containment strategies, occupational exposure limits, and manufacturing best practices will be at the forefront. This HPAPI Conference will highlight best practices in delivering high-potency compounds while optimizing safety, quality, and speed to clinic.
HPAPI Containment and Process Development Conference Innovations
Key topics at the highly potent APIs event will include innovations in HPAPI Containment, isolator and closed-system technology, ADC payload manufacturing, and advanced process development.
A strong focus will also be placed on occupational exposure banding and containment design for HPAPI Conference environments, where precision, safety, and cross-contamination control are critical to ensuring worker protection and product quality. By integrating cutting-edge technologies into facility design and process engineering, the industry is enabling safer, more resilient potent compound manufacturing.
A major focus of the event will be the advancement of HPAPI manufacturing technologies and potent compound handling. As a leading HPAPI Conference and Highly Potent APIs Summit, the event will highlight innovative approaches to cytotoxic handling, flow chemistry, cleaning validation, analytical control, and scalable HPAPI Process Development. Sessions will also examine how modern HPAPI practices are improving compliance, scalability, and long-term manufacturing reliability.
Collaboration at the HPAPI Event and Highly Potent APIs Summit
The 2nd Highly Potent APIs Summit will bring together stakeholders from pharma, biotech, CDMOs, engineering, EHS, and regulatory affairs to discuss the future of highly potent APIs, HPAPI Containment, and potent compound manufacturing. This HPAPI event is a unique opportunity to collaborate, exchange insights, and explore solutions to the industry's most pressing challenges.
Don't Miss the 2nd Highly Potent APIs Summit
As Europe accelerates its potent compound ambitions, collaboration and innovation are more important than ever. Attend our HPAPI Manufacturing and Containment conference, a key highly potent APIs event, to stay ahead of industry trends, discover new technologies, and connect with experts shaping the future of potent drug development.
This Highly Potent APIs Summit will empower you to play a key role in advancing HPAPI safety and building the next generation of potent compound manufacturing.
Be part of the conversation shaping the future of highly potent APIs in Munich, Germany this April 2027.
April 6-7, 2027 | Munich, Germany
Conference learning points
- Market trends: How rising HPAPI demand is changing manufacturing strategy, outsourcing and investment in high-containment capacity
- Containment strategy: Turning potency data, OELs and OEBs into practical containment from development to commercial production
- EHS & worker safety: Risk assessment, exposure monitoring, PPE and training for highly potent operations
- Validation: Cleaning validation, cross-contamination control and analytical method sensitivity
- Containment technology: Isolators, closed transfer, single-use systems, automation and robotics
- Scale-up: Moving from early development to GMP manufacturing while keeping process control, quality and operator safety
- Digitalization: Pharma 4.0 and data-driven monitoring for compliance, performance and continuous improvement
- Cleaning & waste: Decontamination and waste strategies that balance safety, sustainability, cost and regulatory requirements
Sponsors
We offer a number of sponsorship options designed to meet your strategic goals. If you are interested in seeing our detailed sponsorship packages, please reach out to us by clickingĀ theĀ linkĀ below.
Become a SponsorPrevious attendees
Gallery
Registration packages
Media partners
Our top 5 attractions
Marienplatz
Marienplatz has been Munich's central square since the city's foundation and still stands as the centre of social activity in the city, much as it has throughout history. Visit the fanous glockenspiel, admire the MariensƤule and shop at local boutiques.
The Englischer Garten
Munich's English Garden is not only the largest city park in Germany, it's also one of the most beautiful. Naturally arranged groups of flora, nine kilometres of winding streams, and an artificial lake complete the impression of a natural landscape. The park also contains the Bavarian National Museum.
BMW Museum and BMW Welt
Located in the Olympic Park, the BMW Museum offers a look at the storied history of the automotive brand with examples of nearly every model they have produced and their story. The BMW Welt, however, is all about now, with an exhibition area and a three-dimensional media faƧade.
Viktualienmarkt
When the farmers market outgrew Marienplatz, it was moved to the nearby square, where it thrived and expanded, until today it covers 22,000 square meters and includes a bakery, a flower market and mobile kitchens serving hot food in addition to its fruit and vegetable vendors.
Nymphenburg Palace
The home of the Bavarian monarchy, take in the palaceās canals, fountains, magnificent flower gardens and impressive buildings. You can also visit the several museums housed in the palace itself, including the Museum of Man and Nature.
Our top 5 restaurants
Trattoria Da Fausto
Italian cuisine, including a signature tiramisu, amid frescoed walls, climbing plants & chandeliers.
Andy's Krablergarten
Relaxed restaurant & beer garden serving hearty Bavarian sides, grills & schnitzels.
Little London Bar & Grill
Refined, British-inspired Michelin steakhouse & bar offering cocktails & an extensive wine list.
Hofbräuhaus München
3-floor beer hall dating back to the 16th century, with a Bavarian restaurant, shows & upbeat vibe.
ONE Nation Munich
Health-conscious bowls, wraps & smoothies offered in a relaxed restaurant with a leafy terrace.
Frequently Asked Questions
Containment strategies for highly potent APIs protect operators and prevent cross-contamination during handling, weighing, and processing. Isolators, closed-system transfer, and engineered controls are matched to the compound’s potency and occupational exposure band. A well-designed containment approach is essential for worker safety, regulatory compliance, and consistent product quality in HPAPI manufacturing.
Antibody-drug conjugates rely on highly potent cytotoxic payloads that demand specialized synthesis, handling, and quality control. Manufacturing these compounds requires robust containment, validated processes, and careful supply planning. Understanding payload and linker manufacturing is key to bringing ADC and oncology therapies to clinic safely and efficiently.
Flow chemistry and process intensification can reduce operator exposure by using smaller volumes and closed systems. These approaches also improve control, yield, and scalability for potent compound synthesis. Adoption depends on the chemistry involved, equipment readiness, and regulatory expectations for continuous processing.
Facility design for HPAPIs combines containment, airflow, personnel and material flow, and utilities into a safe and efficient layout. Decisions made at the design stage affect operator protection, flexibility, and long-term operating cost. Early collaboration between engineering, EHS, and manufacturing teams leads to stronger outcomes.
Choosing a CDMO for HPAPI work means assessing containment capability, technical expertise, capacity, and quality systems. Clear communication and aligned safety standards are vital throughout technology transfer and scale-up. A well-managed partnership supports supply security and faster progress from development to commercial supply.
Occupational exposure banding classifies potent compounds by their toxicity and acceptable exposure levels. It helps teams define the right handling controls, facility design, and personal protective measures before production begins. Accurate banding supports safe scale-up and reduces the risk of operator exposure across development and manufacturing.
HPAPI process development focuses on building safe, reproducible, and scalable synthesis routes for potent compounds. Scale-up must account for containment limits, yield, impurity control, and equipment design. Early planning for process safety reduces delays and cost as programs move from clinical supply to commercial manufacturing.
Cleaning validation proves that residues of potent compounds are removed to safe, defined limits between batches. In multi-product facilities, it is critical for protecting patients and meeting GMP expectations. Strong analytical methods, health-based exposure limits, and well-designed equipment all support effective cross-contamination control.
Regulators expect manufacturers to demonstrate control over operator safety, cross-contamination, and product quality for potent compounds. In Europe, this includes GMP requirements and health-based exposure limits that shape facility and process decisions. Staying aligned with evolving guidance helps avoid delays during inspections and approvals.
The summit, taking place on April 6-7, 2027, in Munich, Germany, brings together pharma, biotech, CDMO, engineering, and EHS professionals. Attendees gain practical insights into containment, manufacturing, and process development, and can network with peers and solution providers shaping the future of HPAPIs.